EAU guidelines on prostate cancer
EAU guidelines on prostate cancer
复制标题
DOI：
10.1016/j.eururo.2007.09.002
复制
发表时间：
2008-01-01
期刊：
影响因子：
23.4
通讯作者：
Zattoni, Filliberto
中科院分区：
文献类型：
--
作者：
Heidenreich, Axel;Aus, Gunnar;Zattoni, Filliberto
目的：介绍2007年版欧洲泌尿外科协会（EAU）前列腺癌（PCa）指南的总结：工作组对2004年至2007年出现的新数据进行了文献综述。该指南已更新，并增加了证据/等级的建议的文本的基础上，系统的文献综述，其中包括在线数据库和bibliographic reviews.Results的搜索：完整版本可在EAU办公室或在www.uroweb.org.系统性前列腺活检超声引导下是首选的诊断方法。积极治疗主要推荐给局部疾病和预期寿命长的患者，在前瞻性随机试验中，根治性直肠癌切除术上级观察等待。保留神经的根治性前列腺切除术是器官局限性疾病的首选方法;新辅助雄激素剥夺治疗未显示结局变量的改善。低危和中高危PCa的放射治疗剂量分别至少为72和78戈伊。单次雄激素剥夺是转移性PCa的标准治疗;间歇性雄激素剥夺可能是选定患者的替代治疗选择。随访主要是基于前列腺特异性抗原和疾病特异性病史，影像学检查仅显示局部症状。多西他赛细胞毒性治疗已成为转移性前列腺癌难治性PCa.Conclusions的参考治疗：在PCa领域的知识正在迅速变化。这些EAU关于PCa的指南总结了最新的发现并将其应用于临床实践。(C)2007年欧洲泌尿外科协会。Elsevier B. V.出版，保留所有权利。
Objectives: To present a summary of the 2007 version of the European Association of Urology (EAU) guidelines on prostate cancer (PCa).Methods: A literature review of the new data emerging from 2004 to 2007 was performed by the working panel. The guidelines have been updated, and the level of evidence/grade of recommendation was added to the text based on a systematic review of the literature, which included a search of online databases and bibliographic reviews.Results: A full version is available at the EAU Office or at www.uroweb.org. Systemic prostate biopsy under ultrasound guidance is the preferred diagnostic method. Active treatment is mostly recommended for patients with localized disease and a long life expectancy, with radical prostatectomy being shown to be superior to watchful waiting in a prospective randomized trial. Nerve-sparing radical prostatectomy represents the approach of choice in organ-confined disease; neoadjuvant androgen deprivation demonstrates no improvement of outcome variables. Radiation therapy should be performed with at least 72 and 78 Gy in low-risk and intermediate- to high-risk PCa, respectively. Monotherapeutic androgen deprivation is the standard of care in metastatic PCa; intermittent androgen deprivation might be an alternative treatment option for selected patients. Follow-up is largely based on prostate-specific antigen and a disease-specific history with imaging only localized indicated symptoms occur. Cytotoxic therapy with docetaxel has emerged as the reference treatment for metastatic hormone-refractory PCa.Conclusions: The knowledge in the field of PCa is rapidly changing. These EAU guidelines on PCa summarize the most recent findings and put them into clinical practice. (C) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved.